S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   444.28 (-0.12%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   444.28 (-0.12%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   444.28 (-0.12%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,251.47 (+0.06%)
DOW   39,776.66 (+0.04%)
QQQ   444.28 (-0.12%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
LON:AZN

AstraZeneca (AZN) Share Price, News & Analysis

£106.78
-64.00 (-0.60%)
(As of 04:39 PM ET)
Today's Range
£106.74
£107.80
50-Day Range
9,501
£105.90
52-Week Range
9,461
£123.92
Volume
1.27 million shs
Average Volume
2.31 million shs
Market Capitalization
£165.51 billion
P/E Ratio
3,547.51
Dividend Yield
2.14%
Price Target
£117.13

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.1% Upside
£117.13 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

AZN stock logo

About AstraZeneca Stock (LON:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

AZN Stock News Headlines

Only a fool would buy Nvidia today…
Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.
AZN Apr 2024 72.000 call
AZN May 2024 67.500 call
AZN Apr 2024 60.000 put
AZN Apr 2024 67.000 call
Only a fool would buy Nvidia today…
Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.
AZN Mar 2024 57.000 call
AZN Mar 2024 68.000 put
AstraZeneca Stock (NASDAQ:AZN) Insider Trades
AstraZeneca Prices $5bln Four Tranche Notes Offering
AZN Oct 2024 62.500 put
AZN Feb 2024 69.000 call
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/25 Dividend
2/22/2024
Dividend Payable
3/25/2024
Today
3/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
89,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
£117.13
High Stock Price Target
£135
Low Stock Price Target
GBX 9,500
Potential Upside/Downside
+9.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
£5.95 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£45.81 billion
Cash Flow
GBX 275.21 per share
Book Value
GBX 2,525 per share

Miscellaneous

Outstanding Shares
1,550,000,000
Free Float
N/A
Market Cap
£165.90 billion
Optionable
Not Optionable
Beta
0.17
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Pascal Soriot D.V.M. (Age 65)
    M.B.A., CEO & Executive Director
    Comp: $4.57M
  • Dr. Aradhana Sarin M.D. (Age 50)
    CFO & Executive Director
    Comp: $2.52M
  • Ms. Pam P. Cheng (Age 54)
    EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
  • Mr. Andrew P. Barnett
    Head of Investor Relations
  • Mr. Jeffrey Pott
    CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Nicolas Pangalos Ph.D. (Age 57)
    Executive Vice-President
  • Dr. Ruud Dobber Ph.D.
    Executive Vice-President of BioPharmaceuticals Business Unit
  • Dr. Susan Mary Galbraith M.D. (Age 58)
    Ph.D., Executive Vice President of Oncology Research & Development
  • Mr. Leon Wang
    Executive VP of International & China President

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AstraZeneca was last updated on Tuesday, March 26, 2024 at 10:04 PM.

Pros

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • AstraZeneca's recent successful drug trials have shown promising results, indicating potential revenue growth.
  • The company's strong pipeline of innovative pharmaceutical products positions it well for future market expansion.
  • With a current stock price of $XX, AstraZeneca offers an attractive entry point for investors looking for value.
  • AstraZeneca's strategic partnerships and collaborations enhance its research capabilities and market reach.
  • The company's focus on sustainability and corporate responsibility can attract socially conscious investors.

Cons

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • Regulatory challenges and uncertainties in the pharmaceutical industry can impact AstraZeneca's operations and profitability.
  • Competition from other pharmaceutical companies may pose a threat to AstraZeneca's market share and pricing power.
  • Fluctuations in currency exchange rates could affect AstraZeneca's international revenue and earnings.
  • Unexpected adverse effects or setbacks in clinical trials could lead to significant financial losses for the company.
  • Changes in healthcare policies and regulations globally may impact AstraZeneca's pricing strategies and market access.

AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price target for 2024?

10 Wall Street research analysts have issued 12-month target prices for AstraZeneca's shares. Their AZN share price targets range from GBX 9,500 to £135. On average, they anticipate the company's stock price to reach £117.13 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2024?

AstraZeneca's stock was trading at £106 at the beginning of 2024. Since then, AZN shares have increased by 1.3% and is now trading at £107.34.
View the best growth stocks for 2024 here
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Thursday, February 8th. Shareholders of record on Thursday, February 22nd will be paid a dividend of GBX 156 per share on Monday, March 25th. This represents a yield of 1.49%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a boost from the stock's previous dividend of GBX 71.80. The official announcement can be accessed at this link.
Read our dividend analysis for AZN
.

Is AstraZeneca a good dividend stock?

AstraZeneca (LON:AZN) pays an annual dividend of GBX 228 per share and currently has a dividend yield of 2.17%. The dividend payout ratio is 7,574.75%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AZN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners